{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:40Z","timestamp":1792057720078,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xops.2026.101367","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:16Z","timestamp":1787008636000},"page":"101367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2863","authenticated-orcid":false,"given":"Katie F.","family":"Maass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Gune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101367_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2026.101367_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.xops.2026.101367_bib3","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"14","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.xops.2026.101367_bib4","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101367_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13643-021-01864-6","article-title":"Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis","volume":"10","author":"Tricco","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.xops.2026.101367_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/cer-2018-0058","article-title":"The economic and humanistic burden of patients in receipt of current available therapies for nAMD","volume":"7","author":"Jaffe","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.xops.2026.101367_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101367_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101367_bib9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101367_bib10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101367_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration 2-year results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101367_bib12","series-title":"Susvimo [package insert]","year":"2025"},{"key":"10.1016\/j.xops.2026.101367_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101367_bib14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","article-title":"Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times","volume":"100","author":"Fauser","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101367_bib15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajo.2014.05.025","article-title":"Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration","volume":"158","author":"Fauser","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101367_bib16","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ophtha.2012.07.041","article-title":"Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab","volume":"119","author":"Muether","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101367_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.11.13","article-title":"Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema","volume":"13","author":"Diack","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101367_bib18","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/jcph.2290","article-title":"Population pharmacokinetics of ranibizumab delivered via the Port Delivery System implanted in the eye in patients with neovascular age-related macular degeneration","volume":"63","author":"K\u00e5gedal","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xops.2026.101367_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2022.03.005","article-title":"In-vitro characterization of ranibizumab release from the Port Delivery System","volume":"345","author":"Yohe","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.xops.2026.101367_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2018.05.007","article-title":"Development and validation of a novel semi-homogenous clinical assay for quantitation of ranibizumab in human serum","volume":"461","author":"Lowe","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.xops.2026.101367_bib21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.oret.2024.06.012","article-title":"Supplemental intravitreal ranibizumab injections in eyes treated with the Port Delivery System with ranibizumab in the Archway trial","volume":"8","author":"Nielsen","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101367_bib22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526003052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526003052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:23:31Z","timestamp":1792056211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526003052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666914526003052"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101367","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamics of Free VEGF After Treatment with the Port Delivery Platform with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101367"}}